Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer - PubMed
4 hours ago
- #ovarian cancer
- #FXR1
- #siRNA therapy
- FXR1 is amplified and overexpressed in ovarian and other cancers, regulating oncogene translation.
- LNA-modified siRNA (siFXR1-LNA) enhances stability, uptake, and inhibits tumor growth, ascites, and metastasis more effectively than native siRNA.
- silencing FXR1 suppresses tumor cell proliferation and reduces M2-like macrophages while boosting anti-tumor immune cells like cytotoxic T cells, NK cells, and dendritic cells.
- FXR1 is identified as a key therapeutic target for siRNA-based treatment in ovarian cancer.